The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis.
Open accessAbstract
Exposure of human ovarian tumor cell lines to cisplatin led to development of cell lines that exhibited increasing degrees of drug resistance, which were closely correlated with increase of the levels of cellular glutathione. Cell lines were obtained that showed 30- to 1000-fold increases in resistance; these cells also had strikingly increased (13- to 50-fold) levels of glutathione as compared with the drug-sensitive cells of origin. These levels of resistance to cisplatin and the cellular glutathione levels are substantially greater than previously reported. Very high cisplatin resistance was associated with enhanced expression of mRNAs for gamma-glutamylcysteine synthetase and gamma-glutamyl transpeptidase; immunoblots showed increase of gamma-glutamylcysteine synthetase but not of glutathione synthetase. Glutathione S-transferase activity was unaffected, as determined with chlorodinitrobenzene as a substrate. These studies suggest the potential value of examining regulation of glutathione synthesis as an indicator of clinical prognosis. The highly resistant cell lines are proving useful for studying the multiple mechanisms by which tumor cells acquire drug- and radiation-resistance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bradford, M. M. (1976) · Analytical Biochemistry · doi:10.1016/0003-2697(76)90527-3 · Cited by 255,302
Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4
LAEMMLI, U. K. (1970) · Nature · doi:10.1038/227680a0 · Cited by 249,961
Raza, H., John, A., & Nemmar, A. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350087 · Cited by 47,221
Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction
Chomczynski, P., & Sacchi, N. (1987) · Analytical Biochemistry · doi:10.1016/0003-2697(87)90021-2 · Cited by 46,426
Meister, A., & Anderson, M. E. (1983) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.52.070183.003431 · Cited by 5,680
Self-citationGriffith, O. W. (1980) · Analytical Biochemistry · doi:10.1016/0003-2697(80)90139-6 · Cited by 4,602
Hansen, M. B., Nielsen, S. E., & Berg, K. (1989) · Journal of Immunological Methods · doi:10.1016/0022-1759(89)90397-9 · Cited by 3,507
[51] Assays for differentiation of glutathione S-Transferases
Habig, W. H., & Jakoby, W. B. (1981) · Methods in Enzymology · doi:10.1016/s0076-6879(81)77053-8 · Cited by 2,419
Griffith, O. W., & Meister, A. (1979) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)35980-5 · Cited by 1,683
Self-citationFluorometric assay of proteins in the nanogram range
Böhlen, P., Stein, S., Dairman, W., & Udenfriend, S. (1973) · Archives of Biochemistry and Biophysics · doi:10.1016/s0003-9861(73)80023-2 · Cited by 1,632
Cited by
Cisplatin: mode of cytotoxic action and molecular basis of resistance
Siddik, Z. H. (2003) · Oncogene · doi:10.1038/sj.onc.1206933 · Cited by 3,335
Structure, Recognition, and Processing of Cisplatin−DNA Adducts
Jamieson, E. R., & Lippard, S. J. (1999) · Chemical Reviews · doi:10.1021/cr980421n · Cited by 2,949
Lu, S. C. (2013) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2012.09.008 · Cited by 2,166
From Krebs to clinic: glutamine metabolism to cancer therapy
Altman, B. J., Stine, Z. E., & Dang, C. V. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.71 · Cited by 2,119
Regulation of glutathione synthesis
Lu, S. C. (2009) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2008.05.005 · Cited by 2,116
Molecular mechanisms of resistance and toxicity associated with platinating agents
Rabik, C. A., & Dolan, M. E. (2007) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2006.09.006 · Cited by 1,564
Role of Glutathione in Cancer Progression and Chemoresistance
Traverso, N., Ricciarelli, R., Nitti, M., Marengo, B., Furfaro, A. L., Pronzato, M. A., Marinari, U. M., & Domenicotti, C. (2013) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2013/972913 · Cited by 1,208
“In addition, it has been demonstrated that GGT-overexpressing cells were more resistant to hydrogen peroxide [67] and chemotherapics, such as doxorubicin [68], cisplatin [64], and 5-fluorouracil [69].”
BackgroundNiu, B., Liao, K., Zhou, Y., Wen, T., Quan, G., Pan, X., & Wu, C. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.121110 · Cited by 1,168
Ovarian cancer: strategies for overcoming resistance to chemotherapy
Agarwal, R., & Kaye, S. B. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1123 · Cited by 1,154
Mechanisms of resistance to cisplatin
Kartalou, M., & Essigmann, J. M. (2001) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/s0027-5107(01)00141-5 · Cited by 869
Glutathione-Associated Enzymes In Anticancer Drug Resistance
Tew, K. D. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-3143 · Cited by 856
Regulation of hepatic glutathione synthesis: current concepts and controversies
Lu, S. C. (1999) · The FASEB Journal · doi:10.1096/fasebj.13.10.1169 · Cited by 856
The interaction between ferroptosis and lipid metabolism in cancer
Li, D., & Li, Y. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00216-5 · Cited by 703
Engineering nanomedicine for glutathione depletion-augmented cancer therapy
Xiong, Y., Xiao, C., Li, Z., & Yang, X. (2021) · Chemical Society Reviews · doi:10.1039/d0cs00718h · Cited by 692
Cellular responses to cisplatin. The roles of DNA-binding proteins and DNA repair.
Chu, G. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)42175-2 · Cited by 651
Cisplatin nephrotoxicity: a review of the literature
Manohar, S., & Leung, N. (2018) · Journal of Nephrology · doi:10.1007/s40620-017-0392-z · Cited by 636
Müller, M., Meijer, C., Zaman, G. J., Borst, P., Scheper, R. J., Mulder, N. H., de Vries, E. G., & Jansen, P. L. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.26.13033 · Cited by 617
Cisplatin resistance and opportunities for precision medicine
Amable, L. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.01.001 · Cited by 589
Cellular Responses to Cisplatin‐Induced DNA Damage
Basu, A., & Krishnamurthy, S. (2010) · Journal of Nucleic Acids · doi:10.4061/2010/201367 · Cited by 569
Ishikawa, T., & Ali-Osman, F. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(20)80702-9 · Cited by 533
Controlling Tumor Growth by Modulating Endogenous Production of Reactive Oxygen Species
Laurent, A., Nicco, C., Chéreau, C., Goulvestre, C., Alexandre, J., Alves, A., Lévy, E., Goldwasser, F., Panis, Y., Soubrane, O., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.948.65.3 · Cited by 509
Role of oxidative and nitrosative stress in cisplatin-induced nephrotoxicity
Chirino, Y. I., & Pedraza-Chaverri, J. (2009) · Experimental and Toxicologic Pathology · doi:10.1016/j.etp.2008.09.003 · Cited by 489
Konstantinopoulos, P. A., Spentzos, D., Karlan, B. Y., Taniguchi, T., Fountzilas, E., Francoeur, N., Levine, D. A., & Cannistra, S. A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.5719 · Cited by 483
The Role of Cellular Accumulation in Determining Sensitivity to Platinum-Based Chemotherapy
Hall, M. D., Okabe, M., Shen, D.-W., Liang, X.-J., & Gottesman, M. M. (2008) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.48.080907.180426 · Cited by 474
Cisplatin: a review of toxicities and therapeutic applications
Barabas, K., Milner, R., Lurie, D., & Adin, C. (2008) · Veterinary and Comparative Oncology · doi:10.1111/j.1476-5829.2007.00142.x · Cited by 446
Lung glutathione and oxidative stress: implications in cigarette smoke-induced airway disease
Rahman, I., & MacNee, W. (1999) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.1999.277.6.l1067 · Cited by 420
Marzano, C., Gandin, V., Folda, A., Scutari, G., Bindoli, A., & Rigobello, M. P. (2007) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2006.12.021 · Cited by 415
Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy
Reed, E. (1998) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(98)90056-1 · Cited by 397
Effect of curcumin on normal and tumor cells: Role of glutathione and bcl-2
Syng-ai, C., Kumari, A. L., & Khar, A. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.1101.3.9 · Cited by 395
Applications of Raman spectroscopy in cancer diagnosis
Auner, G. W., Koya, S. K., Huang, C., Broadbent, B., Trexler, M., Auner, Z., Elias, A., Mehne, K. C., & Brusatori, M. A. (2018) · Cancer and Metastasis Reviews · doi:10.1007/s10555-018-9770-9 · Cited by 385
Self-citationCellular and molecular determinants of cisplatin resistance
Perez, R. P. (1998) · European Journal of Cancer · doi:10.1016/s0959-8049(98)00227-5 · Cited by 384
Glutathione-Depleting Nanomedicines for Synergistic Cancer Therapy
Cheng, X., Xu, H.-D., Ran, H.-H., Liang, G., & Wu, F.-G. (2021) · ACS Nano · doi:10.1021/acsnano.1c00498 · Cited by 374
Induction of ferroptotic cell death for overcoming cisplatin resistance of head and neck cancer
Roh, J.-L., Kim, E. H., Jang, H. J., Park, J. Y., & Shin, D. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.07.035 · Cited by 373
Singh, A., Boldin-Adamsky, S., Thimmulappa, R. K., Rath, S. K., Ashush, H., Coulter, J., Blackford, A., Goodman, S. N., Bunz, F., Watson, W. H., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1401 · Cited by 367
Clinical Perspectives on Platinum Resistance
Giaccone, G. (2000) · Drugs · doi:10.2165/00003495-200059004-00002 · Cited by 364
Liao, L., Liu, J., Dreaden, E. C., Morton, S. W., Shopsowitz, K. E., Hammond, P. T., & Johnson, J. A. (2014) · Journal of the American Chemical Society · doi:10.1021/ja502011g · Cited by 362
Strategies for reversing drug resistance
Fojo, T., & Bates, S. (2003) · Oncogene · doi:10.1038/sj.onc.1206951 · Cited by 357
Sherman-Baust, C. A., Weeraratna, A. T., Rangel, L. B. A., Pizer, E. S., Cho, K. R., Schwartz, D. R., Shock, T., & Morin, P. J. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00058-8 · Cited by 339
Urata, Y., Honma, S., Goto, S., Todoroki, S., Iida, T., Cho, S., Honma, K., & Kondo, T. (1999) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(99)00131-8 · Cited by 333
Toward a Better Understanding of the Complexity of Cancer Drug Resistance
Gottesman, M. M., Lavi, O., Hall, M. D., & Gillet, J.-P. (2016) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010715-103111 · Cited by 327
Mechanisms of Resistance to Photodynamic Therapy
Casas, A., Di Venosa, G., Hasan, T., & Batlle, A. (2011) · Current Medicinal Chemistry · doi:10.2174/092986711795843272 · Cited by 322
Metabolism of Cisplatin to a Nephrotoxin in Proximal Tubule Cells
Townsend, D. M., Deng, M., Zhang, L., Lapus, M. G., & Hanigan, M. H. (2003) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000042803.28024.92 · Cited by 317
Shih, A. Y., Erb, H., Sun, X., Toda, S., Kalivas, P. W., & Murphy, T. H. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.3178-06.2006 · Cited by 315
Shi, M. M., Kugelman, A., Iwamoto, T., Tian, L., & Forman, H. J. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)47224-9 · Cited by 307
Myungjin Lee, J., Mhawech-Fauceglia, P., Lee, N., Cristina Parsanian, L., Gail Lin, Y., Andrew Gayther, S., & Lawrenson, K. (2013) · Laboratory Investigation · doi:10.1038/labinvest.2013.41 · Cited by 301
Kondrashova, O., Topp, M., Nesic, K., Lieschke, E., Ho, G.-Y., Harrell, M. I., Zapparoli, G. V., Hadley, A., Holian, R., Boehm, E., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05564-z · Cited by 296
Role of Glutathione in the Regulation of Cisplatin Resistance in Cancer Chemotherapy
Chen, H. H. W., & Kuo, M. T. (2010) · Metal-Based Drugs · doi:10.1155/2010/430939 · Cited by 287
Expression of γ-glutamyltransferase in cancer cells and its significance in drug resistance
Pompella, A., De Tata, V., Paolicchi, A., & Zunino, F. (2006) · Biochemical Pharmacology · doi:10.1016/j.bcp.2005.10.005 · Cited by 280
DNA Repair: Enzymatic Mechanisms and Relevance to Drug Response
Chaney, S. G., & Sancar, A. (1996) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/88.19.1346 · Cited by 280
Increased nucleotide excision repair in cisplatin-resistant ovarian cancer cells
Ferry, K. V., Hamilton, T. C., & Johnson, S. W. (2000) · Biochemical Pharmacology · doi:10.1016/s0006-2952(00)00441-x · Cited by 275
Self-citationHanigan, M. H., & Ricketts, W. A. (1993) · Biochemistry · doi:10.1021/bi00075a026 · Cited by 272
(2014) · Advances in Cancer Research · doi:10.1016/b978-0-12-420117-0.00003-7 · Cited by 271
Lelièvre, P., Sancey, L., Coll, J.-L., Deniaud, A., & Busser, B. (2020) · Cancers · doi:10.3390/cancers12123594 · Cited by 271
Ishikawa, T., Bao, J.-J., Yamane, Y., Akimaru, K., Frindrich, K., Wright, C. D., & Kuo, M. T. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.25.14981 · Cited by 266
Glutathione-Responsive Prodrug Nanoparticles for Effective Drug Delivery and Cancer Therapy
Ling, X., Tu, J., Wang, J., Shajii, A., Kong, N., Feng, C., Zhang, Y., Yu, M., Xie, T., Bharwani, Z., et al. (2019) · ACS Nano · doi:10.1021/acsnano.8b06400 · Cited by 263
Brozovic, A., Ambriović-Ristov, A., & Osmak, M. (2010) · Critical Reviews in Toxicology · doi:10.3109/10408441003601836 · Cited by 261
The Enzymes of Glutathione Synthesis: γ‐Glutamylcysteine Synthetase
Griffith, O. W., & Mulcahy, R. T. (1999) · Advances in Enzymology - and Related Areas of Molecular Biology · doi:10.1002/9780470123195.ch7 · Cited by 253
Transcriptional Activation of the Human Glutathione Peroxidase Promoter by p53
Tan, M., Li, S., Swaroop, M., Guan, K., Oberley, L. W., & Sun, Y. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.17.12061 · Cited by 253
APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells
Mohell, N., Alfredsson, J., Fransson, Å., Uustalu, M., Byström, S., Gullbo, J., Hallberg, A., Bykov, V. J. N., Björklund, U., & Wiman, K. G. (2015) · Cell Death & Disease · doi:10.1038/cddis.2015.143 · Cited by 183
“Figure 5 shows that the glutathione levels were about 3-fold higher in the cisplatin-resistant A2780-CP20 cells than in the A2780 cells, in agreement with the previous results.(15) In both cell lines, APR-246 (Figures 5a and b) and MQ (Figures 5c and d) decreased glutathione in a dose-dependent manner, resulting in de…”
BackgroundResultInfluentialKopetz, S., Lesslie, D. P., Dallas, N. A., Park, S. I., Johnson, M., Parikh, N. U., Kim, M. P., Abbruzzese, J. L., Ellis, L. M., Chandra, J., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2246 · Cited by 160
FAK activity sustains intrinsic and acquired ovarian cancer resistance to platinum chemotherapy
Diaz Osterman, C. J., Ozmadenci, D., Kleinschmidt, E. G., Taylor, K. N., Barrie, A. M., Jiang, S., Bean, L. M., Sulzmaier, F. J., Jean, C., Tancioni, I., et al. (2019) · eLife · doi:10.7554/elife.47327 · Cited by 145
Yao, K., Gietema, J. A., Shida, S., Selvakumaran, M., Fonrose, X., Haas, N. B., Testa, J., & O'Dwyer, P. J. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602864 · Cited by 82
Self-citationBarhoumi, R., Bowen, J. A., Stein, L. S., Echols, J., & Burghardt, R. C. (1993) · Cytometry · doi:10.1002/cyto.990140707 · Cited by 67
Perez, M., Lucena-Cacace, A., Marín-Gómez, L. M., Padillo-Ruiz, J., Robles-Frias, M. J., Saez, C., Garcia-Carbonero, R., & Carnero, A. (2016) · Oncotarget · doi:10.18632/oncotarget.8880 · Cited by 34
Metadata
- Authors
- Godwin, A. K., Meister, A., O'Dwyer, P. J., Huang, C. S., Hamilton, T. C., & Anderson, M. E.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 1992-04
- Volume
- 89
- Issue
- 7
- Pages
- 3070-3074
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2071756286
- Cited by
- 925
- References
- 35
- FWCI
- 9.42
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.